Can clinical guardrails survive the direct-to-consumer software playbook pharma has now adopted?
The same class of technology I use to help front-line workers do their jobs better is being weaponized against anyone with a phone.
VCs are rereading Matt Ridley’s The Rational Optimist – and it’s shaping how they’re betting on AI. Here’s what the book’s core thesis reveals about the venture capital logic behind the current AI supercycle.
Most organizations already have an AI strategy. Where things fall apart is in execution, because AI lives inside the business, not on top of it.
To operate safely at higher development velocity, organizations must embed reliability guardrails directly into their platforms.
The risks presented by Mythos-class models are genuine, but organizations that prepare effectively will retain a strong defensive advantage.
The IPO should boost tax revenue in the Golden State because thousands of newly wealthy employees who live and work there face a “millionaires” tax.
Without the right controls, consumer-facing AI agents can expose organizations to regulatory violations, privacy breaches, eroded trust and reputational damage.
AI will reduce transaction costs and improve many markets. But it will also make some problems cheaper to create, from fraud to pressure on infrastructure.
Even unbroken systems, perfectly deployed, can become liabilities with time.